ACC: Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute coronary syndrome who had percutaneous coronary intervention and remained event-free for one month on dual antiplatelet therapy, according to a study published online April 7 in The Lancet to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.
Zhen Ge, M.D., from Nanjing First Hospital in China, and colleagues conducted a randomized, double-blind trial involving adults with an acute coronary syndrome with percutaneous coronary intervention with stent placement, who had no major ischemic or bleeding events after one-month treatment with dual antiplatelet therapy. Participants were randomly assigned to receive oral ticagrelor plus oral aspirin or oral ticagrelor plus a matching oral placebo (1,700 patients in each group) beginning one month after and ending 12 months after percutaneous coronary intervention.
The researchers found that clinically relevant bleeding occurred in 2.1 and 4.6 percent of patients in the ticagrelor plus placebo group and the ticagrelor plus aspirin group, respectively (hazard ratio, 0.45). Major adverse cardiovascular or cerebrovascular events (MACCE) occurred in 3.6 and 3.7 percent of patients in the ticagrelor plus placebo and ticagrelor plus aspirin groups, respectively.
"The present results show that, in these patients, treatment with a ticagrelor monotherapy regimen between month one and month 12 after the intervention decreases the risk of clinically relevant bleeding events while providing similar protection from MACCE as compared with ticagrelor plus aspirin," the authors write.
Several authors disclosed ties to the pharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Pediatric Resource Use Less Likely With Legalization of Recreational Cannabis
WEDNESDAY, May 1, 2024 -- In cases of cannabis intoxication in children, resource utilization is less likely in states with recreational legalization of cannabis, according to a...
Osteoporosis Screening Rates Low for Asian American Medicare Beneficiaries
WEDNESDAY, May 1, 2024 -- Rates of dual-energy X-ray absorptiometry (DXA) screening for osteoporosis are lower than expected for Asian American Medicare beneficiaries, according...
Long-Term Smell, but Not Taste, Deficits Seen After COVID-19
WEDNESDAY, May 1, 2024 -- Olfactory dysfunction, especially for smell, is more common in individuals with prior COVID-19 versus individuals with no history of infection, with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.